Hosted on MSN28d
Novo's Rybelsus results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...
pharmaphorum5y
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
Later-to-market Ozempic is lagging behind Trulicity, with first-half sales of around $550 million, but has been predicted to reach $2 to $3 billion per year at peak, with Rybelsus having the ...
Yahoo Finance27d
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...
Yahoo Finance29d
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
The study showed that Rybelsus, the company's oral form of semaglutide ... it lowered the odds of life-threatening events like heart attacks and strokes. This positions Novo Nordisk to redefine ...
pharmaphorum6d
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nod
Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...
Seeking Alpha28d
Novo's Rybelsus CV results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...